[1] |
MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
|
[2] |
WANG QX, MA X. Current status and perspectives of autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 721-723. DOI: 10.3969/j.issn.1001-5256.2020.04.001.
王绮夏, 马雄. 自身免疫性肝炎的研究现状与展望[J]. 临床肝胆病杂志, 2020, 36(4): 721-723. DOI: 10.3969/j.issn.1001-5256.2020.04.001.
|
[3] |
LONGHI MS, MIELI-VERGANI G, VERGANI D. Regulatory T cells in autoimmune hepatitis: An updated overview[J]. J Autoimmun, 2021, 119: 102619. DOI: 10.1016/j.jaut.2021.102619.
|
[4] |
WANG H, FENG X, YAN W, et al. Regulatory T cells in autoimmune hepatitis: Unveiling their roles in mouse models and patients[J]. Front Immunol, 2020, 11: 575572. DOI: 10.3389/fimmu.2020.575572.
|
[5] |
CHAUVIN JM, ZAROUR HM. TIGIT in cancer immunotherapy[J]. J Immunother Cancer, 2020, 8(2): e000957. DOI: 10.1136/jitc-2020-000957.
|
[6] |
JI W, PENG X, LOU T, et al. Total flavonoids from Tetrastigma hemsleyanum ameliorates inflammatory stress in concanavalin A-induced autoimmune hepatitis mice by regulating Treg/Th17 immune homeostasis[J]. Inflammopharmacology, 2019, 27(6): 1297-1307. DOI: 10.1007/s10787-019-00599-0.
|
[7] |
WU HY, YANG JL. TIGIT and anti-tumor immunity[J]. Chin J Immunol, 2020, 36(11): 1407-1408, inside back cover. DOI: 10.3969/j.issn.1000-484X.2020.11.025.
吴红艳, 杨建林. TIGIT与抗肿瘤免疫[J]. 中国免疫学杂志, 2020, 36(11): 1407-1408, 封3. DOI: 10.3969/j.issn.1000-484X.2020.11.025.
|
[8] |
YANG ZZ, KIM HJ, WU H, et al. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma[J]. Clin Cancer Res, 2020, 26(19): 5217-5231. DOI: 10.1158/1078-0432.CCR-20-0558.
|
[9] |
ANDERSON AC, JOLLER N, KUCHROO VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation[J]. Immunity, 2016, 44(5): 989-1004. DOI: 10.1016/j.immuni.2016.05.001.
|
[10] |
ZHOU H, LI B, LI J, et al. Dysregulated T cell activation and aberrant cytokine expression profile in systemic lupus erythematosus[J]. Mediators Inflamm, 2019, 2019: 8450947. DOI: 10.1155/2019/8450947.
|
[11] |
LIU S, SUN L, WANG C, et al. Treatment of murine lupus with TIGIT-Ig[J]. Clin Immunol, 2019, 203: 72-80. DOI: 10.1016/j.clim.2019.04.007.
|
[12] |
DENG C, LI W, FEI Y, et al. Imbalance of the CD226/TIGIT immune checkpoint is involved in the pathogenesis of primary biliary cholangitis[J]. Front Immunol, 2020, 11: 1619. DOI: 10.3389/fimmu.2020.01619.
|
[13] |
AKIYAMA M, SUZUKI K, YOSHIMOTO K, et al. Peripheral TIGIT+ T follicular helper cells that produce high levels of interleukin-21 via OX40 represent disease activity in IgG4-related disease[J]. Front Immunol, 2021, 12: 651357. DOI: 10.3389/fimmu.2021.651357.
|
[14] |
NAGAI K. Co-inhibitory receptor signaling in T-cell-mediated autoimmune glomerulonephritis[J]. Front Med (Lausanne), 2020, 7: 584382. DOI: 10.3389/fmed.2020.584382.
|
[15] |
PING YQ, MAO C, XIAO P, et al. Structures of the glucocorticoid-bound adhesion receptor GPR97-Go complex[J]. Nature, 2021, 589(7843): 620-626. DOI: 10.1038/s41586-020-03083-w.
|
[16] |
BUTTGEREIT F, GABER T. New insights into the fascinating world of glucocorticoids: The dexamethasone-miR-342-Rictor axis in regulatory T cells[J]. Cell Mol Immunol, 2021, 18(3): 520-522. DOI: 10.1038/s41423-020-00598-0.
|
[17] |
WANG R, WANG QX, MA X. Standard therapy and potential therapeutic targets for autoimmune hepatitis[J]. J Clin Hepatol, 2020, 36(4): 737-742. DOI: 10.3969/j.issn.1001-5256.2020.04.005.
王睿, 王绮夏, 马雄. 自身免疫性肝炎的标准治疗和潜在治疗靶点[J]. 临床肝胆病杂志, 2020, 36(4): 737-742. DOI: 10.3969/j.issn.1001-5256.2020.04.005.
|
[18] |
LONGHI MS, MA Y, BOGDANOS DP, et al. Impairment of CD4(+) CD25(+) regulatory T-cells in autoimmune liver disease[J]. J Hepatol, 2004, 41(1): 31-37. DOI: 10.1016/j.jhep.2004.03.008.
|
[19] |
TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
|
[20] |
BUITRAGO-MOLINA LE, PIETREK J, NOYAN F, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis[J]. J Autoimmun, 2021, 117: 102591. DOI: 10.1016/j.jaut.2020.102591.
|
[21] |
LAPIERRE P, BÉLAND K, YANG R, et al. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance[J]. Hepatology, 2013, 57(1): 217-227. DOI: 10.1002/hep.26023.
|
[22] |
XIA G, WU S, WANG X, et al. Inhibition of microRNA-155 attenuates concanavalin-A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation[J]. Can J Physiol Pharmacol, 2018, 96(12): 1293-1300. DOI: 10.1139/cjpp-2018-0467.
|
[23] |
HARDTKE-WOLENSKI M, TAUBERT R, NOYAN F, et al. Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens[J]. Hepatology, 2015, 61(4): 1295-1305. DOI: 10.1002/hep.27639.
|
[24] |
LONGHI MS, HUSSAIN MJ, KWOK WW, et al. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis[J]. Hepatology, 2011, 53(2): 536-547. DOI: 10.1002/hep.24039.
|
[25] |
VUERICH M, HARSHE R, FRANK LA, et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis[J]. J Hepatol, 2021, 74(1): 48-57. DOI: 10.1016/j.jhep.2020.06.044.
|
[26] |
RAFFIN C, VO LT, BLUESTONE JA. Treg cell-based therapies: Challenges and perspectives[J]. Nat Rev Immunol, 2020, 20(3): 158-172. DOI: 10.1038/s41577-019-0232-6.
|
[27] |
LUCCA LE, AXISA PP, SINGER ER, et al. TIGIT signaling restores suppressor function of Th1 Tregs[J]. JCI Insight, 2019, 4(3): e124427. DOI: 10.1172/jci.insight.124427.
|